Casdin Capital 13F holdings, Q2 2020
Holdings as of June 30, 2020 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 42 US equity positions worth $1.7bn in its Q2 2020 13F filing. The largest position was INVITAE CORP at 16.2% of the reported book, followed by 2655787D and FATE. Against the Q1 2020 filing, it opened 7 new positions, added to 11 and reduced 10 among the top 42 holdings.
What did Casdin Capital own in Q2 2020? Top 42 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2020 |
|---|---|---|---|---|---|---|---|
| 1 | INVITAE CORP | 16.2% | $273.6m | 9,033,943 | 160% | added | |
| 2 | 2655787D BLUEPRINT MEDICINES CORP | 7.2% | $120.9m | 1,550,000 | 0% | held | |
| 3 | FATE FATE THERAPEUTICS INC | Healthcare | 6.2% | $104.6m | 3,050,000 | 20% | added |
| 4 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 5.0% | $85.0m | 530,000 | -21% | reduced |
| 5 | MYOKARDIA INC | 5.0% | $84.1m | 870,000 | -13% | reduced | |
| 6 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 4.8% | $81.5m | 550,000 | -6% | reduced |
| 7 | BLFS BIOLIFE SOLUTIONS INC | Healthcare | 4.7% | $79.3m | 4,849,524 | 96% | added |
| 8 | BLUEBIRD BIO INC | 4.0% | $67.4m | 1,105,000 | 0% | held | |
| 9 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 3.4% | $57.2m | 1,070,000 | 0% | held |
| 10 | CDXS CODEXIS INC | Healthcare | 3.2% | $53.5m | 4,692,732 | -8% | reduced |
| 11 | BNR BURNING ROCK BIOTECH LTD | 2.8% | $46.7m | 1,730,786 | – | new | |
| 12 | TWST TWIST BIOSCIENCE CORP | Healthcare | 2.7% | $45.3m | 1,000,000 | 0% | held |
| 13 | CDNA CAREDX INC | Healthcare | 2.5% | $42.3m | 1,193,335 | -8% | reduced |
| 14 | RVMD REVOLUTION MEDICINES INC | Healthcare | 2.5% | $42.1m | 1,334,536 | 1% | added |
| 15 | ADVERUM BIOTECHNOLOGIES INC | 2.3% | $38.9m | 1,865,000 | 66% | added | |
| 16 | ADPT ADAPTIVE BIOTECHNOLOGIES COR | Healthcare | 2.0% | $34.5m | 713,125 | -10% | reduced |
| 17 | GENERATION BIO CO | 2.0% | $33.8m | 1,611,214 | – | new | |
| 18 | DNLI DENALI THERAPEUTICS INC | Healthcare | 1.9% | $31.7m | 1,310,000 | -10% | reduced |
| 19 | CNST CONSTELLATION PHARMCETICLS I | 1.7% | $29.4m | 980,000 | 0% | held | |
| 20 | ONC BEIGENE LTD | Healthcare | 1.7% | $28.3m | 150,000 | – | new |
| 21 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 1.6% | $26.8m | 625,000 | 25% | added |
| 22 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 1.6% | $26.4m | 1,441,176 | 19% | added |
| 23 | ALEC ALECTOR INC | Healthcare | 1.6% | $26.3m | 1,076,039 | 0% | held |
| 24 | MAGENTA THERAPEUTICS INC | 1.5% | $25.1m | 3,346,034 | 13% | added | |
| 25 | AMYRIS INC | 1.4% | $22.8m | 5,349,376 | – | new | |
| 26 | CRSP CRISPR THERAPEUTICS AG | Healthcare | 1.2% | $19.6m | 266,430 | 0% | held |
| 27 | GLOBAL BLOOD THERAPEUTICS IN | 1.1% | $18.9m | 300,000 | 0% | held | |
| 28 | DERMTECH INC | 1.1% | $18.9m | 1,428,572 | 150% | added | |
| 29 | ZLAB ZAI LAB LTD | Healthcare | 0.9% | $15.6m | 190,000 | 0% | held |
| 30 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 0.8% | $13.0m | 1,455,000 | 0% | held |
| 31 | 2JQ GRITSTONE ONCOLOGY INC | 0.7% | $12.3m | 1,850,373 | -18% | reduced | |
| 32 | BLACK DIAMOND THERAPEUTICS I | 0.7% | $12.2m | 289,395 | 0% | held | |
| 33 | ILMN ILLUMINA INC | Healthcare | 0.7% | $11.1m | 30,000 | 0% | held |
| 34 | BRISTOL-MYERS SQUIBB CO | 0.6% | $10.6m | 2,950,000 | 18% | added | |
| 35 | ORCHARD THERAPEUTICS PLC | 0.6% | $9.9m | 1,650,000 | 69% | added | |
| 36 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 0.6% | $9.5m | 750,000 | -32% | reduced |
| 37 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 0.5% | $8.5m | 251,515 | – | new |
| 38 | LEGN LEGEND BIOTECH CORP | Healthcare | 0.3% | $5.7m | 135,000 | – | new |
| 39 | TURNING POINT THERAPEUTICS I | 0.3% | $4.8m | 75,000 | 0% | held | |
| 40 | ZYME ZYMEWORKS INC | Healthcare | 0.3% | $4.7m | 130,000 | – | new |
| 41 | DECIPHERA PHARMACEUTICALS IN | 0.2% | $3.9m | 65,000 | -54% | reduced | |
| 42 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.2% | $2.9m | 120,000 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.